ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Outcomes of Adjunctive Corticosteroid Treatment in Hypoxemic Adults Hospitalized for Mycoplasma pneumoniae Pneumonia: A Retrospective Cohort Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Review
- Adjunctive betamethasone treatment of hypoxaemic adults hospitalised withThe Lancet regional health. Europe · 2026Article
- From Respiratory Pathogen to Systemic Threat: RethinkingMicroorganisms · 2026Review
- Macrolide-resistantFrontiers in pediatrics · 2026Article
- Prediction of risk factors for respiratory failure in children with mycoplasma pneumoniae pneumonia based on clinical pulmonary infection scores.Frontiers in pediatrics · 2026Article
- Growing Threat of Macrolide-ResistantJournal of Korean medical science · 2025Review
- Clinical characteristics of Mycoplasma pneumoniae compared to Streptococcus pneumoniae in hospitalized adults with community-acquired pneumonia- a prospective study.BMC infectious diseases · 2025Article
- Resurgence of Mycoplasma pneumoniae infections in children: emerging challenges and opportunities.Current opinion in infectious diseases · 2025Review
- Correlation analysis between clinical characteristics of adult patients with Mycoplasma pneumoniae pneumonia and 23S rRNA A2063 gene in alveolar lavage fluid.BMC pulmonary medicine · 2025Article
- Epidemiology, Characteristics, and Treatment Outcomes ofOpen forum infectious diseases · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCorticosteroids appears to be beneficial for severe Mycoplasma pneumoniae pneumonia in children, but data in adults are limited. This study investigated effects of adjunctive corticosteroids in hypoxemic adults with M. pneumoniae pneumonia.
methodsAdults admitted 2013-2017 with verified M. pneumoniae pneumonia and hypoxemia (SpO2 < 93% or oxygen treatment) were included in a cohort. Treatment was defined as receipt of at least 1 glucocorticoid dose.Primary outcome was time to regression of hypoxemia, analyzed with a multivariable Cox regression. Secondary outcomes included fever duration, length of stay, and complications.
resultsCorticosteroids were given to 31% (122/388) during hypoxemia. Median age was 44 (interquartile range [IQR] 34-57) years. Median time to start of corticosteroid treatment was 1.9 (IQR 0.6-3.6) days from admission. Median cumulative dose was equivalent to 15 (IQR 10-19) mg betamethasone. Treatment duration was 5 (IQR 3-6) days. Patients treated with corticosteroids had more severe respiratory disease, longer symptom duration, and were more often treated with fluoroquinolones.Time to regression of hypoxemia (hazard ratio [HR] 0.92 [95% confidence interval {CI}: .72-1.19], P = .53) and length of stay (HR 0.91 [95% CI: .71-1.16], P = .44) were not significantly different between corticosteroid treated and controls. Corticosteroid treatment was associated to shorter fever duration (HR 1.44 [95% CI: 1.00-2.06], P = .046). Complications did not differ significantly between treatment groups.
conclusionsAdjunctive corticosteroids were not associated with reduced time to regression of hypoxemia in adults with M. pneumoniae pneumonia. However, duration of fever was shorter and no increase in complications was seen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.